The soluble form of the insulin-like growth factor II (IGF-II)/mannose 6-P (IGF-II/ M6P) receptor is released by cells in culture and circulates in the serum. It retains its ability to bind IGF-II and blocks IGF-II-stimulated DNA synthesis in isolated rat hepatocytes. Because these cells are not nor
β¦ LIBER β¦
Dominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancer
β Scribed by Jodi L. Kreiling; Michelle A. Montgomery; Joseph R. Wheeler; Jennifer L. Kopanic; Christopher M. Connelly; Megan E. Zavorka; Jenna L. Allison; Richard G. MacDonald
- Book ID
- 114826252
- Publisher
- John Wiley and Sons
- Year
- 2012
- Tongue
- English
- Weight
- 538 KB
- Volume
- 279
- Category
- Article
- ISSN
- 1432-1327
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Soluble insulin-like growth factor II/ma
β
Carolyn D. Scott; Jocelyn Weiss
π
Article
π
2000
π
John Wiley and Sons
π
English
β 172 KB
π 1 views
Interactions of the receptor for insulin
β
Richard R. Roth; Cynthia Stover; Joji Hari; David O. Morgan; Michele C. Smith; V
π
Article
π
1987
π
Elsevier Science
π
English
β 799 KB
Ξ²-Galactosidase decreases the binding af
β
Wieland KIESS; Cheryl L. THOMAS; Mark M. SKLAR; S. Peter NISSLEY
π
Article
π
1990
π
John Wiley and Sons
π
English
β 806 KB
Developmental regulation of insulin-like
β
Mercedes Ballesteros; Carolyn D. Scott; Robert C. Baxter
π
Article
π
1990
π
Elsevier Science
π
English
β 412 KB
Decreased prostate cancer cell migration
β
Christopher P Evans; Fred Elfman; Gerald Cunha; Marc A Shuman
π
Article
π
1997
π
Elsevier Science
π
English
β 337 KB
Insulin-induced redistribution of the in
β
Laurence Villevalois-Cam; Khadija Tahiri; Geneviève Chauvet; Bernard Desbuquois
π
Article
π
2000
π
John Wiley and Sons
π
English
β 217 KB
π 1 views
The ability of acute insulin treatment to elicit a redistribution of the liver insulin-like growth factor-II/ mannose 6-phosphate (IGF-II/M6P) receptor has been studied in rats, using cell fractionation. Injection of insulin (0.4 -50 g) led to a time-and dose-dependent decrease in IGF-II binding act